Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Pharmtechnology LLC clinical trials
The registry lists 27 studies whose lead sponsor is Pharmtechnology LLC. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Jan 19, 2024.
Keep track of what changes. Save the Pharmtechnology LLC studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesPhase
- Phase 1
- 27
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Pharmtechnology LLC.
- Pharmtechnology LLC27 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 27 of 27.
- Bioequivalence Study of Perindopril Tablets in Healthy Volunteers Under Fasting ConditionsRecruitingNCT06213610Phase 1
- Bioequivalence Study of Two Formulations of Atorvastatin Film-coated Tablets 40 mg in Healthy Volunteers Under Fasting ConditionsCompletedNCT05642845Phase 1
- Bioequivalence Study of Two Formulations of Tablets Ramipril/Hydrochlorothiazide 10 mg/25 mg in Healthy Volunteers Under Fasting ConditionsCompletedNCT05685277Phase 1
- Single Dose Crossover Comparative Bioavailability Study of Two Formulations of Fluconazole 200 mg in Healthy Adult Subjects Under Fasting ConditionsCompletedNCT04038008Phase 1
- Bioequivalence Study of Two Formulations of Clopidogrel Film-coated Tablets 75 mg in Healthy Male Subjects Under Fasting ConditionsCompletedNCT05934799Phase 1
- Bioequivalence Study of Perindopril /Amlodipine/Indapamide 8 mg (10 mg)/2.5 mg/10 mg Tablets in Healthy Volunteers Under Fasting ConditionsStatus unknownNCT05940909Phase 1
- Bioequivalence Study of Two Formulations of Torasemide Tablet 10 mg in Healthy Volunteers Under Fasting ConditionsCompletedNCT04921566Phase 1
- Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting ConditionsCompletedNCT05438316Phase 1
- Bioequivalence Study of Two Formulations of Tablets Aceclofenac 100 mg in Healthy Volunteers Under Fasting ConditionsCompletedNCT05339373Phase 1
- Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting ConditionsCompletedNCT05061901Phase 1
- Bioequivalence Study of Two Formulations of Sildenafil Tablet 100 mg in Healthy Male Volunteers Under Fasting ConditionsStatus unknownNCT04882826Phase 1
- Bioequivalence Study of Two Formulations of Etoricoxib Tablets 120 mg in Healthy Volunteers Under Fasting ConditionsStatus unknownNCT04830579Phase 1
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 10 mg in Healthy Male Volunteers in Fasting ConditionsStatus unknownNCT04753489Phase 1
- Bioequivalence Study of Two Formulations of Rivaroxaban Tablets 20 mg in Healthy Male Volunteers Under Fed ConditionsStatus unknownNCT04729998Phase 1
- A Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil/ Hydrochlorothiazide After a Single Oral Dose Administration Under Fasting ConditionsStatus unknownNCT04138888Phase 1
- The Bioequivalence Study of Two Different Formulations of Candesartan Cilexetil After a Single Oral Dose Administration Under Fasting ConditionsCompletedNCT04012307Phase 1
- The Bioequivalence Study of Two Different Formulations of Olmesartan Medoxomil After a Single Oral Dose Administration Under Fasting Conditions.CompletedNCT03951051Phase 1
- Bioequivalence Study of Two Formulations of Febuxostat 120 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting ConditionsCompletedNCT03918551Phase 1
- Bioequivalence Study of Sotalol, Tablets, 160 mg (Pharmtechnology LLC, Belarus), and Sotalex ®, Tablets, 160 mg (Bristol-Myers Squibb GmbH & Co. KGaA, Germany), in Healthy Volunteers Under Fasting ConditionsCompletedNCT03799536Phase 1
- Bioequivalence Study of Two Formulations of Propafenone 300 mg Film-coated Tablets in Healthy Adult Volunteers After a Single Oral Dose Administration Under Fasting ConditionsCompletedNCT03915340Phase 1
- Bioequivalence Study of Montelukast, 5 mg Chewable Tablets (Pharmtechnology LLC, Belarus), and Singulair®, 5 mg Chewable Tablets (Merck Sharp & Dohme B.V., the Netherlands), in Healthy Volunteers Under Fasting ConditionsCompletedNCT03898193Phase 1
- A Bioequivalence Study of Two Formulations Lamotrigine 100 mg Tablets and Lamictal 100 mg Tablets in Healthy Adult Volunteers Under Fasting ConditionsCompletedNCT03898011Phase 1
- Bioequivalence Study of Clavamox, Film-coated Tablets, 875 mg + 125 mg Pharmtechnology LLC, Belarus), and Augmentin®, Film-coated Tablets, 875 mg + 125 mg (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting ConditionsCompletedNCT03702894Phase 1
- Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting StateCompletedNCT03705533Phase 1
- A Bioequivalence Study of Losartan Potassium Tablets (Containing Losartan Potassium 100 mg) in Normal, Healthy, Adults Under Fasting ConditionsCompletedNCT03459911Phase 1
- Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting ConditionsCompletedNCT03561558Phase 1
- Bioequivalence Study of Clavamox, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (Pharmtechnology LLC, Belarus), and Augmentin®, Powder for Oral Suspension, 400 mg + 57 mg / 5 ml (GlaxoSmithKline Trading CJSC, Russia), in Healthy Volunteers Under Fasting ConditionsCompletedNCT03616301Phase 1